NICE Secures Breakthrough HTA Decision for Prostate Cancer
NICE issues breakthrough HTA decision on Bayer’s prostate cancer therapy.
Industry Trends
NICE accelerates breakthrough framework for complex liver diseases
NICE drives innovation, reshaping MASH evaluations with transformative guidance.
Novartis secures triumphant $12 billion takeover of Avidity
The billion-dollar acquisition advances Avidity’s RNA platform with momentum.
Biogen Secures Breakthrough Edge in Immunology with $1B Vanqua Buy
Biogen strengthens Immunology pipeline through $1B Vanqua acquisition deal.
Poland Makes Historic Leap in Healthcare: Record Number of New Therapies Now Reimbursed
Poland’s Ministry of Health has announced its largest-ever reimbursement list update
Pfizer Throws Down $7.3B Gauntlet in Obesity Race with Metsera Buyout
After internal setbacks, Pfizer is buying its way into the obesity drug market.
FDA’s BsUFA III Framework: What It Means for Biosimilar Sponsors
FDA defines biosimilar PAS & CBE under BsUFA III
Focus Brief: Market Access Weekly September 1 to 7, 2025
Global market access shifts: HTA speed, UK pricing, digital disruption.
The Big Bet: Health Care Deal Spotlight for September 1 to 7, 2025)
Healthcare deal spotlight September 1 to 7, 2025
NCPE Recommends Conditional Access for Omeprazole
NCPE recommends Omeprazole Appizped for reimbursement eligibility.